Rocket Pharmaceuticals, Inc.
RCKT
$3.39
-$0.15-4.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.58% | 28.44% | 36.70% | 45.86% | 57.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.19% | -4.43% | 4.01% | 6.11% | 7.21% |
| Operating Income | 8.19% | 4.43% | -4.01% | -6.11% | -7.21% |
| Income Before Tax | 1.04% | 1.16% | -1.12% | -7.79% | -6.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.04% | 1.16% | -1.12% | -7.79% | -6.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.04% | 1.16% | -1.12% | -7.79% | -6.00% |
| EBIT | 8.19% | 4.43% | -4.01% | -6.11% | -7.21% |
| EBITDA | 8.75% | 5.72% | -3.41% | -5.29% | -6.44% |
| EPS Basic | 16.44% | 16.01% | 3.24% | 5.41% | 9.00% |
| Normalized Basic EPS | 20.53% | 16.72% | 1.72% | 6.24% | 9.75% |
| EPS Diluted | 16.44% | 16.01% | 3.24% | 5.41% | 9.00% |
| Normalized Diluted EPS | 20.53% | 16.72% | 1.72% | 6.24% | 9.75% |
| Average Basic Shares Outstanding | 18.43% | 17.68% | 4.49% | 13.94% | 16.49% |
| Average Diluted Shares Outstanding | 18.43% | 17.68% | 4.49% | 13.94% | 16.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |